Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: A randomized trial

JAMA

Volumn 307, Issue 13, 2012, Pages 1383-1393

  Alberts, Steven R ^a   Sargent, Daniel J ^a   Nair, Suresh ^b   Mahoney, Michelle R ^a   Mooney, Margaret ^c   Thibodeau, Stephen N ^a   Smyrk, Thomas C ^a   Sinicrope, Frank A ^a   Chan, Emily ^d   Gill, Sharlene ^e   Kahlenberg, Morton S ^f   Shields, Anthony F ^g   Quesenberry, James T ^h   Webb, Thomas A ⁱ   Farr, Gist H ^j   Pockaj, Barbara A ^k   Grothey, Axel ^a   Goldberg, Richard M ^l  

^a MAYO CLINIC ROCHESTER   (United States)

^b LEHIGH VALLEY HOSPITAL   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^e BRITISH COLUMBIA CANCER AGENCY   (Canada)

^f Surgical Oncology Associates of South Texas   (United States)

^g KARMANOS CANCER INSTITUTE   (United States)

^h Siouxland Hematology Oncology Associates   (United States)

ⁱ Clinical Oncology Program   (United States)

^j OCHSNER CLINIC FOUNDATION   (United States)

^k MAYO CLINIC   (United States)

^l OHIO STATE UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; ANTINEOPLASTIC AGENT; KRAS PROTEIN, HUMAN; MONOCLONAL ANTIBODY; ONCOPROTEIN; PLATINUM COMPLEX; RAS PROTEIN;

ACNE; ADULT; ADVERSE OUTCOME; AGED; ANOREXIA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; COLON ADENOCARCINOMA; COLON CANCER; CONTROLLED STUDY; DIARRHEA; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GENE EXPRESSION REGULATION; GENE MUTATION; HEART INFARCTION; HUMAN; HYPOMAGNESEMIA; INFECTION; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; ONCOGENE K RAS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PARESTHESIA; PNEUMONIA; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; STOMATITIS; SURVIVAL TIME; THROMBOSIS; TREATMENT DURATION; WEIGHT REDUCTION; WILD TYPE; ADJUVANT CHEMOTHERAPY; CLINICAL TRIAL; COLON TUMOR; CONTROLLED CLINICAL TRIAL; GENETICS; MIDDLE AGED; MUTATION; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; MUTATION; ORGANOPLATINUM COMPOUNDS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84859403854     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2012.385     Document Type: Article

References (33)

1. Moertel CG, Fleming TR, Macdonald JS, et al. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med. 1995;122(5):321-326.
2. André T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350 (23):2343-2351. (Pubitemid 38702845)
3. André T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009;27 (19):3109-3116.
4. Kuebler JP, Wieand HS, O'Connell MJ, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol. 2007;25(16):2198-2204. (Pubitemid 46954643)
5. Bokemeyer C, Bondarenko I, Makhson A, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2009;27(5):663-671.
6. Douillard J-Y, Siena S, Cassidy J, et al. Randomized, phase III trial of panitumumabwith infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2010;28(31):4697-4705.
7. Di Nicolantonio F, Martini M, Molinari F, et al. Wildtype BRAF is required for response to panitumumabor cetuximab in metastatic colorectal cancer. J Clin Oncol. 2008;26(35):5705-5712.
8. Saltz LB, Niedzwiecki D, Hollis D, et al. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. J Clin Oncol. 2007;25(23):3456-3461. (Pubitemid 47310883)
9. Van Cutsem E, Labianca R, Bodoky G, et al. Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J Clin Oncol. 2009;27(19): 3117-3125.
10. Ychou M, Raoul JL, Douillard JY, et al. A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802). Ann Oncol. 2009; 20(4):674-680.
11. National Cancer Institute. Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, Version 3.0, DCTD, NCI, NIH, DHHS. March 31, 2003. http://ctep.cancer.gov. Accessed March 12, 2012.
12. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics. 1979;35(3): 549-556. (Pubitemid 10242750)
13. Pocock SJ, Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics. 1975;31(1):103- 115.
14. Bokemeyer C, Bondarenko I, Hartmann JT, et al. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol. 2011; 22(7):1535-1546.
15. Kaplan EL, Meier P. Nonparametric estimation for incomplete observations. J Am Stat Assoc. 1958; 53(282):457-481.
16. Cox DR. Regression models and life tables. J R Stat Soc [Ser A]. 1972;B34(2):187-200.
17. R Development Core Team (2011). R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2011. http://www.R-project.org/. Accessed March 1, 2012.
18. National Cancer Institute. A Manual for Participants in Clinical Trials of Investigational Agents Sponsored by DCTD, NCI. http://ctep.cancer.gov /investigatorResources/docs/hndbk.pdf. Accessed March 5, 2012.
19. Van Cutsem E, Köhne C-H, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360 (14):1408-1417.
20. Adams RA, Meade AM, Seymour MT, et al. Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer. Lancet Oncol. 2011;12(7):642-653.
21. Tveit K, Guren T, Glimelius B, et al. Randomized phase III study of 5-fluorouracil/floinate/oxaliplatin given continuously or intermittently with or without cetuximab, as first-line treatment of metastatic colorectal cancer [abstract]. AnnOncol. 2010;21(suppl 8): viii9.
22. Adams RA, Meade AM, Madi A, et al. Toxicity associated with combination oxaliplatin plus fluoropyrimidine with or without cetuximab in the MRC COIN trial experience. Br J Cancer. 2009;100(2):251- 258.
23. De Roock W, Claes B, Bernasconi D, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy- refractory metastatic colorectal cancer. Lancet Oncol. 2010;11(8):753-762.
24. Iiizumi M, Liu W, Pai SK, Furuta E, Watabe K. Drug development against metastasis-related genes and their pathways: a rationale for cancer therapy. Biochim Biophys Acta. 2008;1786(2):87-104.
25. Riethdorf S, Wikman H, Pantel K. Review: biological relevance of disseminated tumor cells in cancer patients. Int J Cancer. 2008;123(9):1991- 2006.
26. Natalwala A, Spychal R, Tselepis C. Epithelialmesenchymal transition mediated tumourigenesis in the gastrointestinal tract. World J Gastroenterol. 2008; 14(24):3792-3797.
27. Hugo H, Ackland ML, Blick T, et al. Epithelialmesenchymal and mesenchymal-epithelial transitions in carcinoma progression. J Cell Physiol. 2007; 213(2):374-383. (Pubitemid 47509716)
28. Shin S-Y, Rath O, Zebisch A, et al. Functional roles of multiple feedback loops in extracellular signalregulated kinase and Wnt signaling pathways that regulate epithelial-mesenchymal transition. Cancer Res. 2010;70(17):6715-6724.
29. Karamouzis MV, Konstantinopoulos PA, Papavassiliou AG. Targeting MET as a strategy to overcome crosstalk-related resistance to EGFR inhibitors. Lancet Oncol. 2009;10(7):709-717.
30. Buck E, Eyzaguirre A, Barr S, et al. Loss of homotypic cell adhesion by epithelial-mesenchymal transition or mutation limits sensitivity to epidermal growth factor receptor inhibition. Mol Cancer Ther. 2007; 6(2):532-541. (Pubitemid 46332455)
31. Vincenzi B, Schiavon G, Silletta M, Santini D, Tonini G. The biological properties of cetuximab. Crit Rev Oncol Hematol. 2008;68(2):93-106.
32. Bardelli A, Siena S. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol. 2010;28(7):1254- 1261.
33. Kruser TJ, Wheeler DL. Mechanisms of resistance to HER family targeting antibodies. Exp Cell Res. 2010;316(7):1083-1100.